Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancer Resource Center

News
Quality Oncology Practice Initiative Finds Low Rates of Pre-Treatment Staging Imaging Among Patients With Rectal Cancer
05/25/2022
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as...
05/25/2022
Journal of Clinical Pathways
Conference Coverage
HRQOL With Nivolumab Plus Chemo vs Chemo Alone Among Patients With Gastrointestinal Cancers
10/04/2021
Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...
Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...
Compared with chemotherapy...
10/04/2021
Journal of Clinical Pathways
Conference Coverage
Changes in PROs Can Predict Treatment Response and Survival in Metastatic Gastrointestinal Cancer
10/04/2021
Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.
Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.
Results from a study presented...
10/04/2021
Journal of Clinical Pathways
Quiz
Quiz: Regionalized Gastric Cancer Care
08/27/2021
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization...
08/27/2021
Journal of Clinical Pathways
News
Clinical Outcomes After Implementation of Regionalized Gastric Cancer Care in an Integrated Healthcare System
08/17/2021
Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
Regionalization of gastric...
08/17/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effective Treatment Strategy for Gastric Cancer
08/05/2021
True or False: Perioperative chemotherapy is a more cost-effective treatment strategy than adjuvant chemoradiotherapy among patients with gastric cancer.
True or False: Perioperative chemotherapy is a more cost-effective treatment strategy than adjuvant chemoradiotherapy among patients with gastric cancer.
True or False: Perioperative...
08/05/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiation for Gastric Cancer
07/20/2021
A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.
A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.
A recent study comparing...
07/20/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiotherapy for Gastric Cancer
07/07/2021
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing...
07/07/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Gastric Cancer
NCCN Updates Clinical Practice Guideline for Gastric Cancer
03/10/2021
The National Comprehensive Cancer Network released an update to its clinical practice guideline for gastric cancer.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for gastric cancer.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
NCCN Updates Clinical Practice Guideline for Esophageal Cancers
03/10/2021
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive Cancer Network released an update to its clinical practice guideline for esophageal and esophageal junction cancers.
The National Comprehensive...
03/10/2021
Journal of Clinical Pathways
High Symptom Burden Among Patients With Advanced Upper GI Cancer Undergoing Chemotherapy
Insights From ASCO 2021
High Symptom Burden Among Patients With Advanced Upper GI Cancer Undergoing Chemotherapy
02/19/2021
Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced...
Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced...
Xin Shelley Wang, MD, MPH, The...
02/19/2021
Journal of Clinical Pathways

Expert Insights

High Symptom Burden Among Patients With Advanced Upper GI Cancer Undergoing Chemotherapy
Insights From ASCO 2021
High Symptom Burden Among Patients With Advanced Upper GI Cancer Undergoing Chemotherapy
02/19/2021
Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced...
Xin Shelley Wang, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, discusses results from a real-world study exploring patient-reported outcomes (PROs) of symptom burden and functioning among patients with advanced...
Xin Shelley Wang, MD, MPH, The...
02/19/2021
Journal of Clinical Pathways
HRQoL Low Among Young Adult Colorectal Cancer Survivors
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
02/04/2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Kimberly Miller, PhD, MPH,...
02/04/2021
Journal of Clinical Pathways
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
ENGAGING EXPERTS
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
02/03/2021
02/03/2021
Journal of Clinical Pathways
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
02/03/2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Laura Miotke, MD, discusses data...
02/03/2021
Journal of Clinical Pathways
High Economic Burden of HCC Treated With Loco-Regional Therapies
ENGAGING EXPERTS
High Economic Burden of HCC Treated With Loco-Regional Therapies
01/27/2021
01/27/2021
Journal of Clinical Pathways
Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC
Videos
Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC
01/26/2021
01/26/2021
Journal of Clinical Pathways
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
01/20/2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Arjun Gupta, MD, discusses...
01/20/2021
Journal of Clinical Pathways
Patients With Advanced HCC Often Do Not Receive Second-Line Therapy in Real-World Practice
Videos
Patients With Advanced HCC Often Do Not Receive Second-Line Therapy in Real-World Practice
01/19/2021
01/19/2021
Journal of Clinical Pathways
Davids Headshot
Interview
Integrating Real-World Evidence and Clinical Trial Data in CLL Management
01/17/2025
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...
In this interview, Matthew S....
01/17/2025
Journal of Clinical Pathways
Romano Headshot
Interview
Personalizing Radiotherapy for Endometrial Cancer: Balancing Innovation and Quality of Life
01/17/2025
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...
In this interview, Kara D....
01/17/2025
Journal of Clinical Pathways
Ma Headshot
Interview
Advancing Biomarker Validation and Emerging Treatments in Metastatic Breast Cancer
01/16/2025
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...
In this interview, Cynthia X....
01/16/2025
Journal of Clinical Pathways
Bhat Headshot
Interview
Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic Leukemia
01/13/2025
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...
In this interview, Seema A....
01/13/2025
Journal of Clinical Pathways
Meisel Headshot
Interview
Improving Early Detection and Treatment for Breast Cancer Patients
01/10/2025
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L. Meisel, MD, discusses advancements in early breast cancer detection, the integration of standard and emerging treatments, strategies for improving patient adherence, and opportunities for optimizing care through...
In this interview, Jane L....
01/10/2025
Journal of Clinical Pathways
BDHC Thumbnail
Videos
Alternative Payment Models in Health Care: Successes, Failures, and What’s Next
01/09/2025
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, discuss the evolution and challenges of alternative payment models, including accountable care organizations (ACOs), the Oncology Care Model (OCM),...
In this Breaking Down Health...
01/09/2025
Cancer Care Business Exchange
Patel Headshot
Interview
Evolving Clinical Pathways for Perioperative Strategies in Resectable NSCLC
01/09/2025
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel, MD, discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of...
In this interview, Sandip Patel,...
01/09/2025
Journal of Clinical Pathways
Interview
Transforming Treatment Pathways for Endometrial Cancer
12/20/2024
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje Backes, MD, The Ohio State University College of Medicine, discusses advancements in novel treatments, the impact of molecular classifications, evolving surgical approaches, barriers to standardizing care, and...
In this interview, Floortje...
12/20/2024
Journal of Clinical Pathways
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
Shaverdian Headshot
Interview
Incorporating Precision Medicine and AI Into NSCLC Radiation Approaches
12/19/2024
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek Shaverdian, MD, discusses the evolving role of radiation therapy in NSCLC treatment, highlighting advancements in precision medicine, the integration of AI, and promising research aimed at improving patient outcomes.
In this interview, Narek...
12/19/2024
Journal of Clinical Pathways

Newsfeed

News
Quality Oncology Practice Initiative Finds Low Rates of Pre-Treatment Staging Imaging Among Patients With Rectal Cancer
05/25/2022
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as...
05/25/2022
Journal of Clinical Pathways
Conference Coverage
HRQOL With Nivolumab Plus Chemo vs Chemo Alone Among Patients With Gastrointestinal Cancers
10/04/2021
Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...
Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...
Compared with chemotherapy...
10/04/2021
Journal of Clinical Pathways
Conference Coverage
Changes in PROs Can Predict Treatment Response and Survival in Metastatic Gastrointestinal Cancer
10/04/2021
Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.
Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.
Results from a study presented...
10/04/2021
Journal of Clinical Pathways
News
Clinical Outcomes After Implementation of Regionalized Gastric Cancer Care in an Integrated Healthcare System
08/17/2021
Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
Regionalization of gastric...
08/17/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiation for Gastric Cancer
07/20/2021
A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.
A recent study comparing perioperative chemotherapy with adjuvant chemoradiotherapy among patients with gastric cancer suggests that perioperative chemotherapy may be more cost-effective.
A recent study comparing...
07/20/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Perioperative Chemotherapy vs Adjuvant Chemoradiotherapy for Gastric Cancer
07/07/2021
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing perioperative chemotherapy and adjuvant chemoradiotherapy for the treatment of gastric cancer identified the more cost-effective treatment of the two.
A recent study comparing...
07/07/2021
Journal of Clinical Pathways
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
02/03/2021
02/03/2021
Journal of Clinical Pathways
News
Using ASCO Value Framework to Compare Treatment Options for HCC
01/21/2021
01/21/2021
Journal of Clinical Pathways
Conference Coverage
Lenvatinib Effective for Unresectable HCC in the Real-World Setting
01/16/2021
01/16/2021
Journal of Clinical Pathways
Conference Coverage
NCCN Guideline Adherence Associated With Improved Patient Outcomes in Anal Cancer
01/15/2021
01/15/2021
Journal of Clinical Pathways
News
Racial Disparities in Immune Checkpoint Inhibitor Treatment and Survival Among Patients With NSCLC
01/15/2025
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...
Disparities in immune checkpoint...
01/15/2025
Journal of Clinical Pathways
News
Social Risks Lower Rates of Preventive Cancer Screenings
01/09/2025
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI Cancer Spectrum investigated the pathways through which social risks affect screening outcomes for breast, cervical, and colorectal cancer (CRC) in patients served in community-based clinics across the US.
A recent study published in JNCI...
01/09/2025
Journal of Clinical Pathways
News
A Deep Learning Model for Predicting Immune Checkpoint Inhibitor Efficacy in NSCLC
01/08/2025
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and validated a deep learning model, Deep-IO, designed to predict the efficacy of immune checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC), according to a study published in JAMA...
Researchers developed and...
01/08/2025
Journal of Clinical Pathways
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Refining Risk Stratification for Myelofibrosis Using Real-World Data
12/20/2024
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in understanding the molecular basis of myelofibrosis (MF), a rare and complex bone marrow disorder, predicting disease outcomes and tailoring treatments remains challenging. A study published in Cancers used real-world...
Despite advancements in...
12/20/2024
Journal of Clinical Pathways
Lisa Herms
Conference Coverage
Impact of Bispecific Antibodies on Treatment Patterns and Patient Characteristics in Multiple Myeloma
12/19/2024
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world utilization of bispecific antibodies for relapsed/refractory multiple myeloma in the US community oncology setting, showing promising results in patient characteristics and uptake, with potential impact on patient...
Learn about the real-world...
12/19/2024
Journal of Clinical Pathways
News
Travel and Financial Burdens Play a Role in Cancer Care
12/19/2024
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel burdens and financial hardship can affect the care patients with cancer receive.
The joint stressors of travel...
12/19/2024
Journal of Clinical Pathways
News
An Evaluation of Endometrial Cancer Guidelines for Optimal Patient Care
12/17/2024
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers compares multiple guidelines on managing endometrial cancer, emphasizing the importance of consistent protocols and the role of molecular classification in optimizing treatment for postmenopausal women.
A review published in Cancers...
12/17/2024
Journal of Clinical Pathways
News
Cancer Predisposition Genes Found in 1 in 10 Patients With Multiple Myeloma
12/17/2024
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients with multiple myeloma may have an unknown cancer predisposition syndrome.
Approximately 10% of patients...
12/17/2024
Journal of Clinical Pathways
News
Exploring Lipid Metabolism Pathways in Endometrial Cancer Growth and Metastasis
12/17/2024
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as obesity and dyslipidemia are closely linked to diagnosis and risk of endometrial cancer (EC). With incidence and mortality rates on the rise, a study in Cell Communication and Signaling analyzed how lipid...
Metabolic disorders such as...
12/17/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Regionalized Gastric Cancer Care
08/27/2021
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization...
08/27/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effective Treatment Strategy for Gastric Cancer
08/05/2021
True or False: Perioperative chemotherapy is a more cost-effective treatment strategy than adjuvant chemoradiotherapy among patients with gastric cancer.
True or False: Perioperative chemotherapy is a more cost-effective treatment strategy than adjuvant chemoradiotherapy among patients with gastric cancer.
True or False: Perioperative...
08/05/2021
Journal of Clinical Pathways
What is the Standard First-Line Therapy for Advanced HCC?
Quiz
What is the Standard First-Line Therapy for Advanced HCC?
12/01/2020
12/01/2020
Journal of Clinical Pathways
Quiz
Quiz: Is Targeted Gene Testing Cost-Effective for Metastatic GIST?
10/09/2020
10/09/2020
Journal of Clinical Pathways
Quiz
Quiz: Is Gastric Cancer Screening With MicroRNA Blood Test Cost-Effective?
10/02/2020
10/02/2020
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
Nov-Dec 2024 Issue Cover

Current Issue

December 2024
Volume 10
Issue 6
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
Quality Oncology Practice Initiative Finds Low Rates of Pre-Treatment Staging Imaging Among Patients With Rectal Cancer
05/25/2022
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as many as half of patients with rectal cancer do not receive proper pre-treatment staging imaging, despite NCCN guideline recommendations for such imaging.
A recent study found that as...
05/25/2022
Journal of Clinical Pathways
Conference Coverage
HRQOL With Nivolumab Plus Chemo vs Chemo Alone Among Patients With Gastrointestinal Cancers
10/04/2021
Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...
Compared with chemotherapy alone, nivolumab added to chemotherapy maintained health-related quality of life with a decreased risk of symptom deterioration in patients with previously untreated advanced or metastatic gastric...
Compared with chemotherapy...
10/04/2021
Journal of Clinical Pathways
Conference Coverage
Changes in PROs Can Predict Treatment Response and Survival in Metastatic Gastrointestinal Cancer
10/04/2021
Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.
Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.
Results from a study presented...
10/04/2021
Journal of Clinical Pathways
Quiz
Quiz: Regionalized Gastric Cancer Care
08/27/2021
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
True or False: Regionalization...
08/27/2021
Journal of Clinical Pathways
News
Clinical Outcomes After Implementation of Regionalized Gastric Cancer Care in an Integrated Healthcare System
08/17/2021
Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.
Regionalization of gastric...
08/17/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use